Advertisement

Chemotherapie metastasierter Keimzelltumoren des Hodens

  • J. T. Hartmann
  • M. Kuczyk
  • F. Mayer
  • F. Honecker
  • C. Bokemeyer

Zusammenfassung

Testikuläre Keimzelltumoren gehören zu den Malignomen des Erwachsenen, die selbst im metastasierten Stadium in hohem Maße heilbar sind. Addiert man die Therapieergebnisse für alle Krankheitsstadien, so liegt die Gesamtüberlebensrate nach 5 Jahren bei circa 80%.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. [1]
    Bajorin DF, Motzer RJ, Rodriquez E et al. (1993a) Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy. J Natl Cancer Inst 85: 60–62CrossRefPubMedGoogle Scholar
  2. [2]
    Bajorin DF, Sarosdy MF, Pfister DG et al. (1993b) Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol 1993b; 11: 598–606Google Scholar
  3. [3]
    Baniel J, Foster RS, Gonin R et al. (1995) Late relapse of testicular cancer. J Clin Oncol 13: 1170–1176PubMedGoogle Scholar
  4. [4]
    Berger CC, Bokemeyer C, Schneider M et al. 5(1995) econdary Raynaud’s phenomenon and other late vascular complications following chemotherapy for testicular cancer. Eur J Cancer 31: 2229–2238Google Scholar
  5. [5]
    Berger CC, Bokemeyer C, Schuppert F et al. (1996) Endocrinological late effects after chemotherapy for testicular cancer. Br J Cancer 73: 1108–1114CrossRefPubMedGoogle Scholar
  6. [6]
    Beyer J, Kramar A, Mandanas R et al. (1996) High-dose chemotherapy as salvage treatment in germ cell tumors: A multivariate analysis of prognostic variables. J Clin Oncol 14: 2638–1645PubMedGoogle Scholar
  7. [7]
    Beyer J, Stenning A, Gerl S et al. (1999) High-dose versus conventional-dose first-salvage treatment in nonseminoma: a matched-pair analysis. Proc Am Soc Clin Oncol 18: 326a (abstr. 1255)Google Scholar
  8. [8]
    Bhatia S, Abonour R, Porcu P et al. (2000) High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol 18: 3346–3351PubMedGoogle Scholar
  9. [9]
    Birch R, Williams S, Cone A et al. (1986) Prognostic factors for favourable outcome in disseminated germ cell tumors. J Clin Oncol 4: 400–407PubMedGoogle Scholar
  10. [10]
    Blijham G (1981) The treatment of advanced testicular carcinoma with high dose chemotherapy and autologous marrow support. Eur J Cancer Clin Oncol 17: 433–441Google Scholar
  11. [11]
    Bokemeyer C, Schmoll HJ (1993) Secondary neoplasms following treatment of malignant germ cell tumors. J Clin Oncol 11: 1703–1709PubMedGoogle Scholar
  12. [12]
    Bokemeyer C, Schmoll HJ, Natt F et al. (1994) Preliminary results of a phase I/II trial of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. J Cancer Res Clin Oncol 120: 754–757CrossRefPubMedGoogle Scholar
  13. [13]
    Bokemeyer C, Schmoll HJ (1995a) Treatment of testicular cancer and the development of secondary malignancies. J Clin Oncol 13: 283–292PubMedGoogle Scholar
  14. [14]
    Bokemeyer C, Schmoll HJ, Kuczyk MA et al. (1995b) Risk of secondary leukemia following high cumulative doses of etoposide during chemotherapy for testicular cancer. J Natl Cancer Inst 87: 58–60CrossRefPubMedGoogle Scholar
  15. [15]
    Bokemeyer C, Köhrmann O, Tischler J et al. (1996a) A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with ‘good-risk’ metastatic non-seminomatous germ cell tumours. Ann Oncol 7: 1015–1021CrossRefPubMedGoogle Scholar
  16. [16]
    Bokemeyer C, Kuczyk MA, Kohne H et al. (1996b) Hematopoietic growth factors and treatment of testicular cancer: biological interactions, routine use and dose-intensive chemo-therapy. Ann Hematol 72: 1–9CrossRefPubMedGoogle Scholar
  17. [17]
    Bokemeyer C, Beyer J, Rüther U et al. (1996c) Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol 7: 31–34CrossRefPubMedGoogle Scholar
  18. [18]
    Bokemeyer C, Berger CC, Kuczyk MA et al. (1996d) Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 14: 2923–2932PubMedGoogle Scholar
  19. [19]
    Bokemeyer C, Berger CC, Hartmann JT et al. (1998a) Analysis of risk factors for cisplatininduced ototoxicity in patients with testicular cancer. Br J Cancer 77: 1355–1362CrossRefPubMedGoogle Scholar
  20. [20]
    Bokemeyer C, Harstrick A, Beyer C et al. (1998b) The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. Semin Oncol 25 (suppl. 4) : 24–32PubMedGoogle Scholar
  21. [21]
    Bokemeyer C, Hartmann JT, Kuczyk MA et al. (1998c) The role of paclitaxel in chemosensitive urological malignancies: current strategies in bladder cancer and testicular germ-cell tumors. World J Urol 16: 155–162CrossRefPubMedGoogle Scholar
  22. [22]
    Bokemeyer C, Gerl A, Schöffski et al. (1999a) Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. J Clin Oncol 17: 512–516PubMedGoogle Scholar
  23. [23]
    Bokemeyer C, Kollmannsberger C, Meisner C et al. (1999b) First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis. J Clin Oncol 17(11): 3450–3456PubMedGoogle Scholar
  24. [24]
    Bokemeyer C, Hartmann JT, Droz JP et al. (2000) Prognostic factors and outcome of patients with extragonadal germ cell tumors (EGGCT). Proc Am Soc Clin Oncol 19: 328a (abstr. 1288)Google Scholar
  25. [25]
    Bokemeyer C, Droz JP, Horwich A et al. (2001) Extragonadal seminoma — an international multicenter analysis of prognostic factors and longterm treatment outcome. Cancer 91:1394–1401CrossRefPubMedGoogle Scholar
  26. [26]
    Bosl GJ, Geller LN, Cirricione C et al. (1983) Multivariate analysis of prognostic variables in patients with metastatic cancer. Cancer Res 43:3403–3404PubMedGoogle Scholar
  27. [27]
    Bosl GJ, Yagoda A, Golbey RB et al. (1985) Role of etoposide-based chemotherapy in the treatment of patients with refractory or relapsing germ cell tumors. Am J Med 78: 423–428CrossRefPubMedGoogle Scholar
  28. [28]
    Bosl GJ, Leitner SP, Atlas SA et al. (1986) Increased plasma renin and aldosterone in patients treated with cisplatin-based chemotherapy for metastatic germ-cell tumors. J Clin Oncol 4: 1684–1689PubMedGoogle Scholar
  29. [29]
    Bosl GJ, Geller NL, Bajorin D et al. (1988) A randomized trial of etoposide+cisplatin versus vinblastine+bleomycin+cisplatin+cyclophosphamide+dactinomycin in patients with good-prognosis germ cell tumor. J Clin Oncol 6: 1231–1238PubMedGoogle Scholar
  30. [30]
    Boyer M, Raghavan D, Harris PJ et al. (1990) Lack of late toxicity in patients treated with cisplatin-containing combination chemotherapy for metastatic testicular cancer. J Clin Oncol 8: 21–26PubMedGoogle Scholar
  31. [31]
    Boyer M, Raghavan D (1992) Toxicity of treatment of germ cell tumors. Sem Oncol 2: 128–142Google Scholar
  32. [32]
    Brenner PC, Harry W, Morse MJ et al. (1996) Simultaneous retroperitoneal, thoracic, and cervical resection of postchemotherapy residual masses in patients with metastatic nonseminomatous germ cell tumors of the testis. J Clin Oncol 14: 1765–1769PubMedGoogle Scholar
  33. [33]
    Broun ER, Nichols CR, Kneebone P et al. (1992) Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann Intern Med 117: 124–128CrossRefPubMedGoogle Scholar
  34. [34]
    Broun ER, Nichols CR, Mandanas R et al. (1995) Dose escalation study of high-dose carboplatin and etoposide with autologous bone marrow support in patients with recurrent and refractory germ cell tumors. Bone Marrow Transplant 16: 353–358PubMedGoogle Scholar
  35. [35]
    Chevreau C, Droz JP, Pico JC et al. (1993) Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumors. Eur Urol 23: 213–218PubMedGoogle Scholar
  36. [36]
    Clemm C, Gerl A, Hentrich M et al. (1995) Chemotherapy for far advanced seminoma. Onkologie 18: 189 (abstr. 909)CrossRefGoogle Scholar
  37. [37]
    Clemm C, Bokemeyer C, Gerl A et al. (2000) Randomized trial comparing cisplatin/etoposide/ifosfamide with carboplatin monochemotherapy in patients with advanced metastatic seminoma. Proc Am Soc Clin Oncol 19: 326a (abstr. 1283)Google Scholar
  38. [38]
    Collins DH, Pugh RCB (1964) Classification and frequency of testicular tumours. Br J Urol 36 (Suppl.): 1CrossRefPubMedGoogle Scholar
  39. [39]
    Coogan CL, Hejase MJ, Wahle GR et al. (1996) Nerve sparing post-chemotherapy retroperitoneal lymph node dissection for advanced testicular cancer. J Urol 156 :1656–1658CrossRefPubMedGoogle Scholar
  40. [40]
    Culine S, Kerbrat P, Bouzy J et al. (1999) Are 3 cycles of Bleomycin, etoposide and cisplatin (3BEP) or 4 cycles of etoposide and cisplatin (4EP) equivalent regimens for patients (pts) with good-risk metastatic non seminomatous germ cell tumors (NSGCT)? Preliminary results of a randomized trial. Proc Am Soc Clin Oncol 18: 309a (abstr. 1188)Google Scholar
  41. [41]
    De Bono JS, Paul J, Simpson A et al. (2000) Improving the outcome of salvage treatment for nonseminomatous germ cell tumours (NSGCT). Br J Cancer 83: 426–430CrossRefPubMedGoogle Scholar
  42. [42]
    de Wit R, Stoter G, Sleijfer DT et al. (1995) Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br J Cancer 71: 1311–1314CrossRefPubMedGoogle Scholar
  43. [43]
    de Wit R, Stoter G, Kaye SB et al. (1997) Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 15: 1837–1843PubMedGoogle Scholar
  44. [44]
    de Wit R, Stoter G, Sleijfer DT et al. (1998) Four cycles of BEP versus four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br J Cancer 78: 828–832CrossRefPubMedGoogle Scholar
  45. [45]
    de Wit R, Louwerens M, de Mulder PH et al. (1999) Management of intermediate-prognosis germ-cell cancer: results of a phase I/II study of Taxol-BEP. Int J Cancer 83(6): 831–833CrossRefPubMedGoogle Scholar
  46. [46]
    de Wit R, Roberts JT, Wilkinson P et al. (2000) Final analysis demonstrating the equivalence of 3 BEP vs. 4 cycles and the 5 day schedule vs. 3 days per cycle in good prognosis germ cell cancer. Proc Am Soc Clin Oncol 19: 326a (abstr. 1281)Google Scholar
  47. [47]
    Decatris MP, Wilkinson PM, Welch RS et al. (2000) High-dose chemotherapy and autologous haematopoietic support in poor risk non-seminomatous germ-cell tumours: an effective first-line therapy with minimal toxicity. Ann Oncol 11: 427–434CrossRefPubMedGoogle Scholar
  48. [48]
    Donohue JP, Fox EP, Williams SD et al. (1994) Persistent cancer in postchemotherapy retroperitoneal lymph-node dissection: outcome analysis. World J Urol 12: 190–195PubMedGoogle Scholar
  49. [49]
    Droz JP, Kramar A, Pico JL (1993) Prediction of long-term response after high-dose chemotherapy with autologous bone marrow transplantation in the salvage treatment of non-seminomatous germ cell tumours. Eur J Cancer 29A: 818–821CrossRefPubMedGoogle Scholar
  50. [50]
    Duchesne GM, Stenning SP, Aass N et al. (1997) Radiotherapy after chemotherapy for metastatic seminoma-a diminishing role. MRC Testicular Tumour Working Party. Eur J Cancer 33: 829–835CrossRefPubMedGoogle Scholar
  51. [51]
    Dunn TA, Grunwald V, Bokemeyer C et al. (1997) Pre-clinical activity of taxol in non-seminomatous germ cell tumor cell lines and nude mouse xenografts. Invest New Drugs 15: 91–98CrossRefPubMedGoogle Scholar
  52. [52]
    Einhorn L, Williams S, Mandelbaum I et al. (1981) Surgical resection in disseminated testicular cancer following chemotherapeutic cytoreduction. Cancer 1981; 48: 904–908Google Scholar
  53. [53]
    Einhorn LH; Stender MJ; Williams SD. Phase II trial of gemcitabine in refractory germ cell tumors. J Clin Oncol. 1999; 17(2): 509–511PubMedGoogle Scholar
  54. [54]
    Ellison M, Mostofi F, Flanigan R. Treatment of the residual retroperitoneal mass after chemotherapy for advanced seminoma. J Urol 1988; 140: 618–620PubMedGoogle Scholar
  55. [55]
    Farhat F, Culine S, Theodore C et al. Cisplatin and ifosfamide with either vinblastine or etoposide as salvage therapy for refractory or relapsing germ cell tumor patients: the Institut Gustave Roussy experience. Cancer 1996; 77: 1193–1197CrossRefPubMedGoogle Scholar
  56. [56]
    Fizazi K, Ragan D, Bokemeyer C et al. (1999) Viable malignant cells after primary chemotherapy for metastatic non-seminomatous germ-cell tumors (NSGCT): Results from an international study. Proc Am Soc Clin Oncol 18 (abstr.)Google Scholar
  57. [57]
    Fossa SD, Borge L, Ass N et al. (1987) The treatment of advanced metastatic seminoma. Experience in 55 cases. J Clin Oncol 5: 1071–1077PubMedGoogle Scholar
  58. [58]
    Fossa SD, Ous S, Lien HH et al. (1989) Post-chemotherapy lymph node histology in radiologically normal patients with metastatic nonseminomatous testicular cancer. J Urol 141: 557–559PubMedGoogle Scholar
  59. [58]
    Fossa SD, Droz JP, Stoter G, et al (1995) Cisplatin, vincristine and ifosphamide combination chemotherapy of metastatic seminoma: results of EORTC trial 30874. EORTC GU Group. Br J Cancer 71: 619–624CrossRefPubMedGoogle Scholar
  60. [59]
    Fossa SD, Kaye SB, Mead GM et al. (1998) Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. J Clin Oncol 16: 716–724PubMedGoogle Scholar
  61. [60]
    Fossa SD; Stenning SP; Gerl A et al. (1999) Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours. Br-J-Cancer 80(9): 1392–1399CrossRefPubMedGoogle Scholar
  62. [61]
    Fox E, Weathers T, Williams S et al. (1993) Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J Clin Oncol 11: 1294–1299PubMedGoogle Scholar
  63. [62]
    Friedman NB (1987) The function of the primordial germ cell in extragonadal tissues. Int J Androl 10(1): 43–49CrossRefPubMedGoogle Scholar
  64. [63]
    Ganjoo KN; Chan RJ; Sharma M et al. (1999) Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma. J Clin Oncol 17(11): 3457–3460PubMedGoogle Scholar
  65. [64]
    Gerl A, Clemm C, Schmeller N et al. (1994) Sequential resection of residual abdominal and thoracic masses after chemotherapy for metastatic non-seminomatous germ cell tumours. Br J Cancer 70: 960–965CrossRefPubMedGoogle Scholar
  66. [65]
    Gerl A, Clemm C, Schmeller N et al. (1995a) Outcome analysis after post-chemotherapy surgery in patients with non-seminomatous germ cell tumours. Ann Oncol 6: 483–488PubMedGoogle Scholar
  67. [66]
    Gerl A, Clemm C, Schmeller N et al. (1995b) Prognosis after salvage treatment for unselected male patients with germ cell tumours. Br J Cancer 72: 1026–1032CrossRefPubMedGoogle Scholar
  68. [67]
    Gietema JA, Sleijfer DTh, Willemse PHB et al. (1992) Long-term follow-up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminomatous testicular cancer. Ann Intern Med 116: 709–715CrossRefPubMedGoogle Scholar
  69. [68]
    Gregory C, Peckham M (1986) Results of radiotherapy for stage II testicular seminoma. Radiother Oncol 6: 285–292CrossRefPubMedGoogle Scholar
  70. [69]
    Hainsworth JD, Williams SD, Einhorn LH et al. (1985) Successful treatment of resistant germinal neoplasms with VP-16 and cisplatin: results of a Southeastern Cancer Study Group trial. J Clin Oncol 3: 666–671PubMedGoogle Scholar
  71. [70]
    Harstrick A, Schmoll HJ, Wilke H et al. (1991) Cisplatin, etoposide and ifosfamide salvage therapy for refractory or relapsed germ cell carcinoma. J Clin Oncol 9: 1549–1555PubMedGoogle Scholar
  72. [71]
    Harstrick A, Schleucher N, Andresen E et al. (1999) Tandem high-dose chemotherapy with carboplatin, etoposide and cyclophosphamide followed by peripheral blood stem cell retransfusion in cisplatin refractory germ cell cancer patients. Proc Am Soc Clin Oncol 18: 327a (abstr. 1259)Google Scholar
  73. [72]
    Hartmann JT, Candelaria M, Kuczyk MA et al. (1997a) Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours. Eur J Cancer 33: 843–847CrossRefPubMedGoogle Scholar
  74. [73]
    Hartmann JT, Schmoll H-J, Kuczyk MA et al. (1997b) Postchemotherapy resections of residual masses from metastatic non-seminomatous testicular germ cell tumors. Ann Oncol 8: 531–538CrossRefPubMedGoogle Scholar
  75. [74]
    Hartmann JT, Kollmannsberger C, Kanz L et al. (1999a) Platinum organ toxicity and possible prevention in patients with testicular cancer. Int J Cancer 83: 866–869CrossRefPubMedGoogle Scholar
  76. [75]
    Hartmann JT, Schmoll HJ, Albrecht C et al. (1999b) Long-term effects on sexual functioning and fertility after treatment of testicular cancer. Br J Cancer 80: 801–807CrossRefPubMedGoogle Scholar
  77. [76]
    Hartmann JT, Kanz L, Bokemeyer C (1999c) Diagnosis and treatment of patients with testicular germ cell cancer. Drugs 58(2) : 257–281CrossRefPubMedGoogle Scholar
  78. [77]
    Hartmann JT, Kuczyk MA, Kollmannsberger C et al. (1999d) Future prospects in the chemotherapy of metastatic nonseminomatous testicular germ-cell cancer. World J Urol 17(5): 324–333CrossRefPubMedGoogle Scholar
  79. [78]
    Hartmann JT, Fels LM, Franzke et al. (2000a) Comparative study of the acute nephrotoxicity from standard dose cisplatin ± ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide. Anticancer Res 20: 1177–1182PubMedGoogle Scholar
  80. [79]
    Hartmann JT, Fels LM, Knop S et al. (2000b) A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors. Invest New Drugs 18: 281–289CrossRefPubMedGoogle Scholar
  81. [80]
    Hartmann JT, Knop S, Fels LM et al. (2000c) The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumors. Anti Cancer Drugs 11: 1–6CrossRefPubMedGoogle Scholar
  82. [81]
    Hartmann JT, Nichols CR, Droz JP et al. (2000d) Extragonadal germ cell tumors (EGGCT) and hematological disorders: Incidence and outcome from an international database. J Natl Cancer Inst 92: 54–61CrossRefPubMedGoogle Scholar
  83. [82]
    Hartmann JT, Nichols CR, Droz JP et al. (2000e) The relative risk of second nongerminal malignancies in patients with extragonadal germ cell tumors. Cancer 88(11): 2629–2635CrossRefPubMedGoogle Scholar
  84. [83]
    Hartmann JT, von Vangerow A, Fels LM et al. (2001a) A randomized trial of amifostine in patients with high dose VIC chemotherapy plus autologous blood stem cell transplantation. Br J Cancer 84: 313–320CrossRefPubMedGoogle Scholar
  85. [84]
    Hartmann JT, Schleucher N, Metzner B et al. (2001b) Phase I/II study of sequential high dose VIP plus paclitaxel supported by PBSC in patients with ‘poor prognosis’ germ cell tumor (GCT). Proc Am Soc Clin Oncol 20: 173a (abstr. 691)Google Scholar
  86. [85]
    Hartmann JT, Nichols CR, Droz JP et al. (2001c) Salvage chemotherapy for patients with relapsed nonseminomatous extragonadal germ cell tumors. J Clin Oncol 19:1641–1648PubMedGoogle Scholar
  87. [86]
    Hendry WF, A’Hern RP, Hetherington JW et al. (1993) Para-aortic lymphadenectomy after chemotherapy for metastatic non-seminomatous germ cell tumours: Prognostic value and therapeutic benefit. Br J Urol 71: 208–213CrossRefPubMedGoogle Scholar
  88. [87]
    Herr HW, Sheinfeld J, Puc HS et al. (1997) Surgery for a post-chemotherapy residual mass in seminoma. J Urol 157: 860–862CrossRefPubMedGoogle Scholar
  89. [88]
    Horwich A, Dearnaley DP, A’Hern R et al. (1992) The activity of single-agent carboplatin in advanced seminoma. Eur J Cancer 28A: 1307–1310CrossRefPubMedGoogle Scholar
  90. [89]
    Horwich A, Paluchowska B, Normann A et al. (1997a) Residual mass following chemotherapy of seminoma. Ann Oncol 8: 37–40CrossRefPubMedGoogle Scholar
  91. [90]
    Horwich A, Sleijfer DT, Fossa SD et al. (1997b) Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: A Multiinstituional Medical Research Council/European Organization for Research and Treatment of Cancer trial. J Clin Oncol 15: 1844–1852PubMedGoogle Scholar
  92. [91]
    Horwich A, Oliver RTD, Wilkinson PM et al. (2000) A Medical Research Council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. Br J Cancer 83:1623–1629CrossRefPubMedGoogle Scholar
  93. [92]
    Jones DM, Amato LC, Pagliari R et al. (1997) Carboplatin (CBDCA) and cyclophosphamide (CTX) and delayed consolidation in advanced seminoma. Proc Am Soc Clin Oncol 16: 323a (abstr. 1149)Google Scholar
  94. [93]
    Josefsen D, Ous S, Hoie J et al. (1993) Salvage treatment in male patients with germ cell tumours. Br J Cancer 67: 568–572CrossRefPubMedGoogle Scholar
  95. [94]
    Kaye B, Mead GM, Fossa S et al. (1998) Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor prognosis metastatic nonseminomatous germ cell tumor: A randomized medical research council/European organization for research and treatment of cancer study. J Clin Oncol 16: 692–701PubMedGoogle Scholar
  96. [95]
    Kollmannsberger C, Beyer J, Droz J-P et al. (1998) Secondary leukemia following high cumulative doses of stoposide in patients treated for advanced germ cell tumors. J Clin Oncol 16: 3386–3391PubMedGoogle Scholar
  97. [96]
    Lampe H, Dearnaley DP, Price A et al. (1995) High-dose carboplatin and etoposide for salvage chemotherapy of germ cell tumours: Eur J Cancer 31A: 717–723PubMedGoogle Scholar
  98. [97]
    Lampe H, Horwich A, Norman A et al. (1997) Fertility after chemotherapy for testicular germ cell cancers. J Clin Oncol 15: 239–245PubMedGoogle Scholar
  99. [98]
    Ledermann JA, Holden L, Newlands ES et al. (1994) The long-term outcome of patients who relapse after chemotherapy for non-seminomatous germ cell tumours. Br J Urol 74: 225–230CrossRefPubMedGoogle Scholar
  100. [99]
    Leitner SP, Bosl GJ, Bajorunas D (1986) Gonadal dysfunction in patients treated for metastatic germ-cell tumors. J Clin Oncol 4: 1500–1505PubMedGoogle Scholar
  101. [100]
    Linkesch W, Krainer M, Wagner A (1992) Phase I/II trial of ultrahigh carboplatin, etoposide, cyclophosphamide with ABMT in refractory or relapsed non-seminomatous germ cell tumors (NSGCT). Proc Am Soc Clin Oncol 11: 196 (abstr. 600)Google Scholar
  102. [101]
    Loehrer PJ, Birch R, Williams SD et al. (1987) Chemotherapy of metastatic seminoma: The Southeastern Cancer Study Group Experience. J Clin Oncol 5: 1212–1220PubMedGoogle Scholar
  103. [102]
    Loehrer PJ, Lauer R, Roth BJ et al. (1988) Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med 109: 540–546CrossRefPubMedGoogle Scholar
  104. [103]
    Loehrer PJ Sr, Johnson D, Elson P et al. (1995) Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol 13: 470–476PubMedGoogle Scholar
  105. [104]
    Loehrer PJ, Gonin R, Nichols CR et al. (1998) Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 16: 2500–2504PubMedGoogle Scholar
  106. [105]
    Logothetis CJ, Samuels ML, Trindade A et al. (1982) The growing teratoma syndrome. Cancer 50: 1629–1635CrossRefPubMedGoogle Scholar
  107. [106]
    Mandelbaum I, Yaw PB, Einhorn LH et al. (1983) The importance of one-stage median sternotomy and retroperitoneal node dissection in disseminated testicular cancer. Ann Thorac Surg 36: 524–528CrossRefPubMedGoogle Scholar
  108. [107]
    Margolin K, Doroshow JH, Ahn C et al. (1996) Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support. J Clin Oncol 14: 2631–2637PubMedGoogle Scholar
  109. [108]
    McCaffrey JA, Mazumdar M, Bajorin DF et al. (1997) Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J Clin Oncol 15: 2559–2563PubMedGoogle Scholar
  110. [109]
    Mead GM, Stenning SP, Cook P et al. (1997) International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers. J Clin Oncol 15: 594–603Google Scholar
  111. [110]
    Meinardi MT, Gietema JA, van der Graaf WTA et al. (2000) Cardiovascular Morbidity in Long-Term Survivors of Metastatic Testicular Cancer. J Clin Oncol 18: 1725–1732PubMedGoogle Scholar
  112. [111]
    Mencel PJ, Motzer RJ, Mazumdar M et al. (1994) Advanced seminoma : Treatment results, survival, and prognostic factors in 142 patients. J Clin Oncol 12: 120–126PubMedGoogle Scholar
  113. [112]
    Motzer RJ, Bajorin DF, Schwartz LH et al. (1994) Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 12: 2277–2283PubMedGoogle Scholar
  114. [113]
    Motzer RJ, Cooper K, Geller NL et al. (1990) The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors. Cancer 66: 2476–2481CrossRefPubMedGoogle Scholar
  115. [114]
    Motzer RJ, Gulati SC, Crown JP et al. (1992) High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Cancer 69: 550–556CrossRefPubMedGoogle Scholar
  116. [115]
    Motzer RJ, Mazumdar M, Subhash CG et al. (1993) Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst 85: 1828–1835CrossRefPubMedGoogle Scholar
  117. [116]
    Motzer RJ, Sheinfeld J, Mazumdar M et al. (1995) Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors. J Clin Oncol 13: 2700–2704PubMedGoogle Scholar
  118. [117]
    Motzer RJ, Mazumdar M, Bosl GJ et al. (1996) High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: Treatment results and prognostic factors for survival and toxicity. J Clin Oncol 14: 1098–1105PubMedGoogle Scholar
  119. [118]
    Motzer RJ, Mazumdar M, Sheinfeld J et al. (2000) Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol 18(6): 1173–1180PubMedGoogle Scholar
  120. [119]
    Mulder POM, de Vries EG, Koops HS et al. (1988) Chemotherapy with maximally tolerable doses of VP-16–123 and cyclophosphamide followed by autologous bone marrow transplantation for the treatment of relapsed or refractory germ cell tumors. Eur J Cancer Clin Oncol 24: 675–679CrossRefPubMedGoogle Scholar
  121. [120]
    Mulders PFA, Oosterhoff GON, Boetse C et al. (1990) The importance of prognostic factors in the individual treatment of patients with disseminated germ cell tumours. Br J Urol 66: 425–429CrossRefPubMedGoogle Scholar
  122. [121]
    Murphy B, Breeden E, Donohue J et al. (1993) Surgical salvage of chemorefractory germ cell tumors. J Clin Oncol 11: 324–329PubMedGoogle Scholar
  123. [122]
    Napier MP, Naraghi A, Christmas TJ et al. (2000) Long-term follow-up of residual masses after chemotherapy in patients with non-seminomatous germ cell tumours. Br J Cancer 83: 1274–1280CrossRefPubMedGoogle Scholar
  124. [123]
    Nichols CR, Tricot G, Williams S et al. (1989) Dose-intensive chemotherapy in refractory germ cell cancer: A phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 7: 932–939PubMedGoogle Scholar
  125. [124]
    Nichols CR, Roth BJ, Heerema N et al. (1990) Hematologic neoplasia associated with primary mediastinal germ-cell tumors. N Engl J Med. 322(20): 1425–1429CrossRefPubMedGoogle Scholar
  126. [125]
    Nichols CR, Williams SD, Loehrer PJ et al. (1991) Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: A Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 7: 1163–1172Google Scholar
  127. [126]
    Nichols CR, Breeden ES, Loehrer PJ (1993) Secondary leukemia associated with a conventional dose of etoposide: review of serial germ cell tumor protocols. J Natl Cancer Inst 85: 36–40CrossRefPubMedGoogle Scholar
  128. [127]
    Nichols CR, Roth BJ, Loehrer PJ et al. (1994) Salvage chemotherapy for recurrent germ cell cancer. Sem Oncol 5 (Suppl. 12): 102–108Google Scholar
  129. [128]
    Nichols CR, Catalano PJ, Crawford ED et al. (1989) Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: An Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B study. J Clin Oncol 16: 1287–1293Google Scholar
  130. [129]
    Osanto S, Bukman A, Van Hoek F et al. (1992) Long-term effects of chemotherapy in patients with testicular cancer. J Clin Oncol 10: 574–579PubMedGoogle Scholar
  131. [130]
    Ozols RF, Ihde DC, Linehan WM et al. (1988) A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors. J Clin Oncol 6: 1031–1040PubMedGoogle Scholar
  132. [131]
    Partyka S, Hutchinson L, Amato R. (1996) Preliminary results of taxol/cisplatin chemotherapy in patients with refractory or relapsed nonseminomatous germ cell tumor. Proc Am Assoc Cancer Res 37: 169 (abstr. 1161)Google Scholar
  133. [132]
    Pedersen-Bjergaard J, Daugaard G, Hansen ST et al. (1991) Increased risk of myelodysplasia and leukemia after etoposide, cisplatin, and bleomycin for germ-cell tumors. Lancet 338(8763): 359–363CrossRefPubMedGoogle Scholar
  134. [133]
    Pizzocaro G, Pasi M, Salvioni R et al. (1985) Cisplatin and etoposide salvage therapy and resection of the residual tumor in pretreated germ cell testicular cancer. Cancer 56: 2399–2403CrossRefPubMedGoogle Scholar
  135. [134]
    Pizzocaro G, Salvioni R, Piva L et al. (1986) Cisplatin combination chemotherapy in advanced seminoma. Cancer 58: 1625–1629CrossRefPubMedGoogle Scholar
  136. [135]
    Puc HS, Heelan R, Mazumdan M et al. (1996) Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan Kettering Cancer Center. J Clin Oncol 14: 454–460PubMedGoogle Scholar
  137. [136]
    Qvist HL, Fossa SD, Ous S et al. (1991) Post-chemotherapy tumour residuals in patients with advanced nonseminomatous testicular cancer. Is it necessary to resect all residual masses? J Urol 145: 300–303PubMedGoogle Scholar
  138. [137]
    Raghavan D, Vogelzang NJ, Bosl GJ et al. (1982) Tumor classification and size in germ-cell testicular cancer: influence on the occurrence of metastases. Cancer 50: 1591–1595CrossRefPubMedGoogle Scholar
  139. [138]
    Rick O, Bokemeyer C, Beyer J et al. (2001) Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stemcell rescue in patients with relapsed or refractory germ cell cancer. J Clin Oncol 19: 81–88PubMedGoogle Scholar
  140. [139]
    Rodenhuis S, De Wit R, De Mulder PMH et al. (1999) A prospective trial of repeated high-dose chemotherapy in relapsing germ cell cancer. Proc Am Soc Clin Oncol 18: 310a (abstr. 1190)Google Scholar
  141. [140]
    Rodriguez E, Mathew S, Reuter V et al. (1992) Cytogenetic analysis of 124 prospectively ascertained male germ cell tumors. Cancer Res 52: 2285–2291PubMedGoogle Scholar
  142. [141]
    Rosti G, Albertazzi L, Salioni R et al. (1992) High-dose chemotherapy supported with autologous bone marrow transplantation (ABMT) in germ cell tumors: a phase two study. Ann Oncol 3: 809–812PubMedGoogle Scholar
  143. [142]
    Roth BJ, Einhorn LH, Greist A (1988) Long-term complications of cisplatin-based chemotherapy for testis cancer. Sem Oncol 15: 345–350Google Scholar
  144. [143]
    Rowinsky EK, Gilbert MR, McGuire WP et al. (1991) Sequences of taxol and cisplatin: A phase I and pharmacologic study. J Clin Oncol 9: 1692–1703PubMedGoogle Scholar
  145. [144]
    Sandler AB, Christou A, Fox S et al. (1998) A phase II trial of paclitaxel in refractory germ cell neoplasms. Cancer 82: 1381–1386CrossRefPubMedGoogle Scholar
  146. [145]
    Saxman SB, Finch D, Gonin R et al. (1998) Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: The Indiana university experience. J Clin Oncol 15: 702–706Google Scholar
  147. [146]
    Schmoll HJ, Harstrick A, Bokemeyer et al. (1993) Single-agent carboplatinum for advanced seminoma. A phase II study. Cancer 72: 237–242CrossRefPubMedGoogle Scholar
  148. [147]
    Siegert W, Beyer J, Strohscheer I et al. (1994) High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group. J Clin Oncol 12: 1223–1231PubMedGoogle Scholar
  149. [148]
    Sleijfer S, Willemse PHB, deVries EGE et al. (1996) Treatment of advanced seminoma with cyclophosphamide, vincristine and carboplatin on an outpatient basis. Br J Cancer 74: 947–950CrossRefPubMedGoogle Scholar
  150. [149]
    Souchon R, Krege S, Schmoll HJ et al. (2000) Interdisciplinary consensus on diagnosis and treatment of testicular germ cell tumors. Results of an update conference based on evidence-based medicine (EBM). Strahlenther Oncol 176: 388–405CrossRefGoogle Scholar
  151. [150]
    Stephens WS, Gonin R, Hutchins GD et al. (1996) Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumour patients. J Clin Oncol 14: 1637–1641PubMedGoogle Scholar
  152. [151]
    Steyerberg EW, Keizer HJ, Zwartendijk J et al. (1993) Prognosis after resection of residual masses following chemotherapy for metastatic nonseminomatous testicular cancer: a multivariate analysis. Br J Cancer 68: 195–200CrossRefPubMedGoogle Scholar
  153. [152]
    Steyerberg EW, Keizer HJ, Stoter G et al. (1994) Predictors of residual mass histology following chemotherapy for metastatic non-seminomatous testicular cancer: a quantitative overview of 996 resections. Eur J Cancer 30: 1231–1239CrossRefGoogle Scholar
  154. [153]
    Steyerberg EW, Keizer HJ, Fossa SD et al. (1995) Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. J Clin Oncol 13: 1177–1187PubMedGoogle Scholar
  155. [154]
    Steyerberg EW, Gerl A, Fossa SD et al. (1998) Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer. J Clin Oncol 16: 269–274PubMedGoogle Scholar
  156. [155]
    Tait D, Peckham MJ, Hendry WF et al. (1984) Post-chemotherapy surgery in advanced non-seminomatous germ-cell testicular tumours: the significance of histology with particular reference to differentiated (mature) teratoma. Br J Cancer 50: 601–609CrossRefPubMedGoogle Scholar
  157. [156]
    The Italian Group for Antiemetic Research (1995) Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 332: 1–5CrossRefGoogle Scholar
  158. [157]
    Tiffany P, Morse MJ, Bosl G et al. (1986) Sequential excision of residual thoracic and retro-peritoneal masses after chemotherapy for stage III germ cell tumours. Cancer 57: 978–983CrossRefPubMedGoogle Scholar
  159. [158]
    Toner GC, Panicek DM, Heelan RT et al. (1990) Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol 8: 1683–1694PubMedGoogle Scholar
  160. [159]
    Travis LB, Andersson M, Gospodarowicz M et al. (2000) Treatment-Associated Leukemia Following Testicular Cancer. J Natl Cancer Inst 92: 1165–1171CrossRefPubMedGoogle Scholar
  161. [160]
    van Leeuwen F, Stiggelbout A, van den Belt-Dusebout A et al. (1993) Second cancer risk following testicular cancer: a follow up study of 1,909 patients. J Clin Oncol 11: 415–424PubMedGoogle Scholar
  162. [161]
    Vogelzang NJ, Bosl GJ, Johnson K. (1981) Raynaud’s phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med 95: 288–292CrossRefPubMedGoogle Scholar
  163. [162]
    Vogelzang NJ, Torkelson JL, Kennedy BJ (1985) Hypomagnesemia, renal dysfunction, and Raynaud’s phenomenon in patients treated with cisplatin, vinblastine, and bleomycin. Cancer 56: 2765–2770CrossRefPubMedGoogle Scholar
  164. [163]
    Weijl NI, Rutten MFJ, Zwinderman AH et al. (2000) Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol 18(10): 2169–2178PubMedGoogle Scholar
  165. [164]
    Williams SD, Birch R, Einhorn LH et al. (1987) Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316: 1435–1440CrossRefPubMedGoogle Scholar
  166. [165]
    Wolff SN, Johnson DH, Hainsworth JD et al. (1984) High dose VP-16–213 monotherapy for refractory germinal malignancies. A phase II study. J Clin Oncol 4: 271–274Google Scholar
  167. [166]
    Wood D, Herr H, Motzer R et al. (1992) Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers. Cancer 70:2354–2357CrossRefPubMedGoogle Scholar
  168. [167]
    Wozniak AJ, Samson MK, Shah NT et al. (1991) A randomized trial of cisplatin, vinblastine, and bleomycin versus vinblastine, cisplatin, and etoposide in the treatment of advanced germ cell tumors of the testis: a Southwest Oncology Group study. J Clin Oncol 9: 70–76PubMedGoogle Scholar
  169. [168]
    Xiao H, Mazumdar M, Bajorin DF et al. (1997) Long-term follow-up of patients with goodrisk germ cell tumors treated with etoposide and cisplatin. J Clin Oncol 15: 2553–2558PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2002

Authors and Affiliations

  • J. T. Hartmann
  • M. Kuczyk
  • F. Mayer
  • F. Honecker
  • C. Bokemeyer

There are no affiliations available

Personalised recommendations